OncoMatch/Clinical Trials/NCT06062745
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Is NCT06062745 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including 18F-fluciclovine and PET/CT for advanced prostate cancer.
Treatment: 18F-fluciclovine · PET/CT — This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: * 18F-fluciclovine-PET/CT scan * Two research blood collections
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 low expression (whole-body SUVmean ≤ 10 by 68Ga-PSMA-11 PET/CT) (SUVmean ≤ 10)
PSMA-low disease defined by whole-body SUVmean ≤ 10 determined by standard-of-care 68Ga-PSMA-11 PET/CT imaging
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- Brigham and Womens Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06062745 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require FOLH1?
Yes, FOLH1 low expression (whole-body SUVmean ≤ 10 by 68Ga-PSMA-11 PET/CT) is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages